What Is FLT3-ITD and How Does It Affect AML Treatment?

FLT3-ITD is a specific genetic mutation found in roughly one in five people diagnosed with acute myeloid leukemia (AML), and it fundamentally changes how the disease behaves and how doctors treat it. The mutation causes a growth-signaling receptor on blood cells to stay permanently switched on, driving leukemia cells to multiply aggressively. Because FLT3-ITD is associated with higher relapse rates and shorter survival compared to AML without this mutation, identifying it at diagnosis is now standard practice and directly shapes the choice of drugs, the timing of stem cell transplants, and long-term maintenance strategies.

How the Mutation Works

FLT3 stands for FMS-like tyrosine kinase 3, a protein that normally sits on the surface of developing blood cells and helps regulate their growth. Under normal conditions, FLT3 only activates when a specific signaling molecule binds to it. The ITD part, which stands for internal tandem duplication, describes what goes wrong: a stretch of DNA within the FLT3 gene gets copied and inserted right next to the original, creating a longer-than-normal version of the gene. This extra DNA causes the FLT3 protein to activate itself without waiting for any external signal, keeping the growth switch permanently in the “on” position.¹ The result is that leukemia cells carrying FLT3-ITD proliferate faster and are harder to kill with standard chemotherapy alone.

A separate type of FLT3 mutation, called FLT3-TKD (tyrosine kinase domain), occurs in about 10% of AML cases and affects a different part of the protein. While FLT3-TKD also activates the receptor abnormally, it tends to carry a less dire prognosis than the ITD form, and the two mutations sometimes require different treatment considerations.

Why FLT3-ITD Carries a Worse Prognosis

Even when patients with FLT3-ITD achieve remission after initial chemotherapy, the leukemia comes back more often. One study tracking patients who were in complete remission found that those with detectable FLT3-ITD residual disease had a four-year relapse rate of about 75%, compared to 33% in patients without it. Four-year overall survival was 31% versus 57%.² The mutation essentially acts as a fuel source for any leukemia cells that survive treatment, allowing them to regrow quickly.

That said, not every FLT3-ITD case carries the same risk. Two factors refine the picture considerably: how much of the mutated gene is present relative to the normal copy, and what other mutations the leukemia carries alongside FLT3-ITD.

Allelic Ratio and Co-Occurring Mutations

When a lab detects FLT3-ITD, it also measures the allelic ratio, which is essentially how dominant the mutant copy is compared to the normal one. A higher ratio means a larger proportion of cells carry the mutation, and this matters for prognosis. Patients with a high allelic ratio have significantly shorter survival than those with a low ratio.³ Current risk classification systems from organizations like the European LeukemiaNet use this ratio as one factor when assigning a patient to a favorable, intermediate, or adverse risk group.

The other mutations riding alongside FLT3-ITD also shift the outlook. For years, the presence of an NPM1 mutation was thought to partially offset the poor prognosis of FLT3-ITD, especially when the allelic ratio was low. However, more recent registry data from FLT3-ITD patients has shown comparable remission rates and survival regardless of NPM1 status, suggesting this offsetting effect may be less reliable than once believed.⁴ The interplay between FLT3-ITD and its companion mutations continues to be an area of active refinement in risk models.

Adding FLT3 Inhibitors to Frontline Chemotherapy

The first targeted drug approved for FLT3-mutated AML was midostaurin, a broadly acting kinase inhibitor added to standard chemotherapy during induction and consolidation. Real-world data from multiple centers has shown an overall response rate of about 88% when midostaurin is combined with intensive chemotherapy, with most patients achieving complete remission. Treatment discontinuation due to side effects was low, at roughly 3.5%.⁵ Compared to chemotherapy alone, adding midostaurin meaningfully improved event-free survival, including in older patients.⁶

Midostaurin’s approval in 2017 was a watershed moment. Before that, FLT3-ITD patients received the same chemotherapy as everyone else, despite their worse outcomes. Having a drug that specifically targeted the mutation changed the treatment landscape. But midostaurin hits many kinases beyond FLT3, and researchers soon pursued more selective inhibitors.

Second-Generation Inhibitors Changed the Equation

Two more selective FLT3 inhibitors have since reached approval: gilteritinib and quizartinib. They differ from midostaurin in their specificity and their clinical settings.

Gilteritinib was the first drug approved specifically for relapsed or refractory FLT3-mutated AML. In a landmark trial, patients receiving gilteritinib lived significantly longer than those given salvage chemotherapy, with median overall survival of about 9.3 months versus 5.6 months. Complete remission with full or partial blood count recovery occurred in 34% of gilteritinib patients compared to about 15% with chemotherapy.⁷ A confirmatory trial in a predominantly Asian population reproduced these findings closely, with gilteritinib roughly doubling median survival compared to salvage chemotherapy.⁸

Quizartinib, meanwhile, earned approval for newly diagnosed FLT3-ITD AML (not all FLT3 mutations, specifically the ITD type). In the QuANTUM-First trial, adding quizartinib to standard chemotherapy and continuing it as maintenance therapy roughly doubled median overall survival: about 32 months versus 15 months with placebo.⁹ Quizartinib is now approved in the United States, Japan, Europe, and the United Kingdom for use during induction, consolidation, and as maintenance monotherapy in adults with newly diagnosed FLT3-ITD AML.¹⁰

Stem Cell Transplant and Post-Transplant Maintenance

For many patients with FLT3-ITD, an allogeneic stem cell transplant (using a donor’s cells) remains a critical part of the treatment plan, especially for those in the adverse-risk category. The transplant offers the best chance of long-term cure by replacing the patient’s bone marrow entirely and enlisting the donor’s immune system against any remaining leukemia. But relapse after transplant has historically been a major problem in FLT3-ITD patients.

This is where post-transplant maintenance with an FLT3 inhibitor comes in. A large German registry analysis found that patients who received FLT3 inhibitor maintenance after transplant had five-year relapse-free survival of 70% compared to 47% without maintenance, and five-year overall survival of 81% versus 57%. Non-relapse mortality was also substantially lower in the maintenance group.¹¹ A smaller study showed that the benefit of maintenance became clear after adjusting for factors like the type of transplant conditioning and donor source, with significant improvement in both disease-free and overall survival.¹² Although not every study has reached the same conclusion, the trend is strong enough that post-transplant FLT3 inhibitor maintenance is increasingly becoming standard of care.

Tracking Leftover Disease

One of the trickiest aspects of treating FLT3-ITD AML is knowing whether treatment has truly eliminated the leukemia or whether small numbers of mutant cells remain hidden in the bone marrow. This concept, called measurable residual disease (MRD), has become a critical prognostic tool. Patients who test positive for FLT3-ITD MRD after achieving remission face a dramatically higher risk of relapse, with one study finding the risk more than tripled.²

Detecting FLT3-ITD at very low levels has historically been difficult because the mutation itself is variable in length and location, making it a poor fit for some standard assays. Newer sequencing-based approaches can now detect as few as one FLT3-ITD-carrying cell among 10,000 normal cells.¹³ More sensitive MRD testing is gradually making its way into routine practice, and results are increasingly being used to guide decisions about transplant timing and maintenance therapy.

How Labs Detect FLT3-ITD

At diagnosis, most centers use one of two methods to detect FLT3-ITD: a traditional approach called fragment analysis (which separates DNA by size to identify the abnormally long ITD sequence) or next-generation sequencing (NGS), which reads the DNA directly. A comparative study found the two methods agree over 99% of the time on whether FLT3-ITD is present, and their measurements of the allelic ratio correlate well with each other.¹⁴ NGS has the added advantage of detecting other mutations simultaneously, which is increasingly useful because co-occurring mutations shape the treatment plan.

When FLT3 Inhibitors Stop Working

Resistance to FLT3 inhibitors is a real and growing clinical challenge. It arises through two broad routes. The first is new mutations within the FLT3 gene itself. The leukemia cells may acquire a secondary change in the FLT3 protein that prevents the drug from binding properly while still keeping the growth signal active. Two of the best-known resistance mutations are called D835Y and F691L, both of which can emerge under treatment with gilteritinib or quizartinib.¹⁵

The second route bypasses FLT3 entirely. Leukemia cells can activate alternative growth pathways, particularly the RAS/MAPK pathway, rendering the FLT3 inhibitor irrelevant even though it is still blocking its intended target. Signals from the bone marrow environment itself can also fuel this bypass, with protective molecules produced by surrounding cells keeping leukemia cells alive despite the drug.¹⁶ This means that even perfectly selective FLT3-targeting drugs can fail if the leukemia finds a detour. Researchers are pursuing next-generation inhibitors designed to overcome the most common on-target resistance mutations, including a compound called XL999 that has shown promising preclinical activity against FLT3-ITD cells carrying the D835Y and F691L changes.¹⁵

Triplet Combinations for Patients Who Cannot Tolerate Intensive Chemo

Not everyone with FLT3-ITD AML is a candidate for intensive induction chemotherapy. Older patients and those with significant other health problems often receive lower-intensity regimens built around a hypomethylating agent (a drug that targets the way genes are switched on and off) combined with venetoclax, a drug that blocks a survival protein leukemia cells depend on. Adding an FLT3 inhibitor as a third agent to this backbone has shown improved remission rates and MRD clearance compared to the two-drug combination, without increasing early mortality.¹⁷ A phase 2 trial of the specific triplet of azacitidine, venetoclax, and gilteritinib in relapsed/refractory patients found a combined complete remission rate of about 27%, with additional patients achieving a leukemia-free state. The trade-off was frequent infectious complications, with about 62% experiencing serious infections.¹⁸ Finding the right balance of efficacy and tolerability in these triplet regimens remains an active area of clinical trials.

Side Effects of FLT3 Inhibitors

A natural concern with any targeted drug is whether it introduces new toxicities on top of what chemotherapy already causes. A systematic review and meta-analysis pooling data from seven randomized trials of midostaurin, gilteritinib, and quizartinib found that FLT3 inhibitors as a class do not significantly increase the overall risk of adverse events compared to standard treatment. The most common problems were blood-count-related, which is expected in leukemia treatment. Among non-blood-related side effects, gastrointestinal symptoms, fever, liver enzyme elevations, and headache were most frequent. The one notable exception was that gilteritinib was associated with a higher risk of elevated liver enzymes compared to the other two drugs. No meaningful difference in side effect profiles was found between midostaurin and quizartinib.

FLT3-ITD in Children

FLT3-ITD occurs in pediatric AML too, and it carries a similarly poor prognosis in children as in adults. However, the treatment landscape differs. Most adult trials of FLT3 inhibitors enrolled only patients 18 and older, so the evidence base for children is thinner. One trial evaluated sorafenib (an older multi-kinase inhibitor with FLT3 activity) added to chemotherapy in children with FLT3-ITD AML and found that while three-year overall survival was 85% in the sorafenib group, this was not statistically different from the non-sorafenib group. In that study, stem cell transplant during first remission was the factor most strongly associated with improved outcomes.¹⁹

What has become increasingly clear in pediatric FLT3-ITD AML is the importance of co-occurring mutations. A large analysis of 464 children and young adults with FLT3-ITD found that about 79% had additional genetic alterations, and these dramatically influenced outcomes. Children whose leukemia harbored both FLT3-ITD and a favorable co-occurring mutation had a five-year event-free survival of 64%, while those with a poor-risk co-occurring mutation had just 22%. In this pediatric population, the co-occurring mutations mattered more for prognosis than the allelic ratio did.²⁰ This finding is pushing pediatric oncologists toward more nuanced risk-stratification models that go well beyond simply checking for the presence or absence of FLT3-ITD.

The Cost Problem

FLT3 inhibitors are expensive, and for many patients and health systems, cost is a real constraint on access. A cost-effectiveness analysis of adding quizartinib to standard induction chemotherapy found that the combination added about $290,000 in costs while gaining roughly 0.84 quality-adjusted life years. That works out to an incremental cost of about $344,000 per quality-adjusted life year, which far exceeds the thresholds most health systems use to judge whether a treatment offers good value. The analysis concluded that only an 87% reduction in quizartinib’s wholesale price, or eliminating the continuation phase of therapy, would bring the cost into a conventionally acceptable range.²¹ This tension between clinical benefit and affordability is not unique to quizartinib; it shadows the entire class of FLT3 inhibitors and shapes who actually receives these drugs outside of clinical trials and well-resourced treatment centers.

Immunotherapy Approaches Targeting FLT3

Beyond small-molecule inhibitors, researchers are exploring whether the immune system can be trained to attack FLT3-expressing leukemia cells directly. Two main strategies are in preclinical and early clinical development. The first uses bispecific antibodies, engineered proteins that physically bridge a leukemia cell and a T cell (an immune killer cell), forcing the T cell to attack. One such molecule, CLN-049, binds FLT3 on the leukemia cell and CD3 on the T cell, and because it targets a part of FLT3 that is present regardless of mutation type, it could work against AML with or without FLT3-ITD.²²

The second approach uses CAR T cells, where a patient’s own T cells are genetically modified to recognize FLT3 on leukemia cells. Preclinical testing of FLT3-directed CAR T cells has shown strong killing of AML cell lines and patient-derived leukemia cells, with minimal damage to normal blood-forming stem cells.²³ A head-to-head preclinical comparison of bispecific antibodies and CAR T cells found that both killed leukemia effectively while sparing healthy cells, though the two approaches showed different patterns of T-cell exhaustion that could influence which works better in actual patients.²⁴ These immunotherapy strategies are still years from routine clinical use, but they represent a fundamentally different angle of attack that could complement or eventually replace small-molecule inhibitors, especially in patients whose leukemia has developed resistance to existing drugs.